Trial Profile
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 24 Aug 2005 New trial record.